Ronelle Moodliar

5 ta ish

Umkhuseli Innovation and Research Management

1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

   Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos

   ABIABI:AkademIndex/2022.article.000002

2. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

   Andrew Nunn, Patrick Phillips, Sarah Meredith +16

   MaqolaOAOchiq kirish20196 iqtibos

   ABIABI:AkademIndex/2026.other.006848

3. Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

   Beverley Stringer, Karen Lowton, M. Cusinato +6

   BoshqaOAOchiq kirish20230 iqtibos

   ABIABI:AkademIndex/2023.other.001840

4. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   MaqolaOAOchiq kirishCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 iqtibos

   ABIABI:AkademIndex/2024.article.000869

5. Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study

   Karen Lowton, Beverley Stringer, M. Cusinato +7

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyIJTLD OPEN20260 iqtibos

   ABIABI:AkademIndex/2026.article.016746